Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(66.7%)

Phase 1

1(33.3%)

3Total

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT05493501Phase 3Terminated

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Role: lead

NCT05712941Phase 3Withdrawn

Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

Role: lead

NCT05199610Phase 1Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Role: lead

NCT05131438Unknown

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

Role: lead

All 4 trials loaded